.jpeg)
用去纤苷需要注意的事项有哪些？
Defiteli (defiteli) is the first drug approved by the U.S. FDA for the treatment of severe hepatic veno-occlusive disease. It is a mixture of sodium salts of single-stranded deoxyoligonucleotides, which is prepared from pig small intestinal mucosal genomic DNA through controlled depolymerization. Its mechanism of action is complex and has not yet been fully elucidated.
Defibrotide is indicated for adult or pediatric patients with hepatic vein obstruction (VOD) and renal or pulmonary function abnormalities after blood or bone marrow hematopoietic stem cell transplantation (HSCT). The drug has also received "orphan drug" designation.
Defibrotide is an injectable drug that needs to be used under the guidance of a professional doctor. The dose is selected based on body weight. The recommended dose is 6.25 mg/kg. It can be used by adults or children.
As a prescription drug, what should you pay attention to when using defibrotide?
1. Defibrinoside increases plasmin activity in vitro, so before using defibrinoside, it must be ensured that the patient has not experienced clinically significant bleeding and is hemodynamically stable on no more than one vasopressin. In order to protect the patient's life and health, patients with active bleeding should not use defibrotide. Other patients need to be monitored for signs of bleeding while taking the drug. If bleeding occurs while taking defibrotide, treatment with the drug should be discontinued, the cause of the disease should be identified, and supportive care should be provided until the bleeding has stopped.
2. Do not co-administer defibrotide and other intravenous drugs in the same intravenous line at the same time.
3. A very small proportion of patients (less than 2%) have experienced hypersensitivity reactions. These reactions include rash, urticaria, and angioedema. If a severe hypersensitivity reaction occurs, discontinue defibrotide, treat with standard medical care, and monitor until symptoms resolve.
4. Drug interactions. Discontinue anticoagulants and fibrinolytics before defibrotide therapy as this may increase the risk of bleeding.
The above are the things you need to pay attention to when treating defibrotide (defiteli). I hope it will be helpful to you.[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
